Are you Dr. Peyrani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
501 E Broadway
Suite 120
Louisville, KY 40202Phone+1 502-852-3905
Summary
- Dr. Paula Peyrani, MD is an infectious disease specialist in Louisville, Kentucky. She is currently licensed to practice medicine in Kentucky. She is affiliated with UofL Health - UofL Hospital and is an Instructor at U of Louisville Sch of Med.
Education & Training
University of Louisville School of MedicineFellowship, Infectious Disease, 2009 - 2011
University of Buenos AiresClass of 1999
Certifications & Licensure
KY State Medical License 2011 - 2025
Clinical Trials
- Failure and Cardiovascular Events in Community-acquired Pneumonia Start of enrollment: 2009 Oct 01
- Patients Response to Early Switch To Oral:Osteomyelitis Study Start of enrollment: 2014 Mar 06
Publications & Presentations
PubMed
- A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal NimenrixVaccine When Given to Healthy Infants at 3 and 12 Mont...Susanna Koski, Federico Martinon-Torres, Mika Rämet, Lefteris Zolotas, Ryan Newton
Infectious Diseases and Therapy. 2025-02-01 - Global Epidemiology of Meningococcal Disease-Causing Serogroups Before and After the COVID-19 Pandemic: A Narrative Review.Steven Shen, Jamie Findlow, Paula Peyrani
Infectious Diseases and Therapy. 2024-12-01 - 2 citationsFrom Qualitative Research to Quantitative Preference Elicitation: An Example in Invasive Meningococcal Disease.Joshua Coulter, Chiara Whichello, Sebastian Heidenreich, Brett Hauber, Christine Michaels-Igbokwe
The Patient. 2024-05-01
Press Mentions
- A Phase 2b/3b MenACWY-TT Study of Long-Term Antibody Persistence After Primary Vaccination and Immunogenicity and Safety of a Booster Dose in Individuals Aged 11 Through 55 YearsJune 18th, 2020
